US Bancorp’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.11K | Buy |
1,000
+800
| +400% | +$5.86K | ﹤0.01% | 3518 |
|
|
2026
Q1 | $1.28K | Hold |
200
| – | – | ﹤0.01% | 3889 |
|
|
2025
Q4 | $1.19K | Hold |
200
| – | – | ﹤0.01% | 3832 |
|
|
2025
Q3 | $1.06K | Hold |
200
| – | – | ﹤0.01% | 3823 |
|
|
2025
Q2 | $686 | Hold |
200
| – | – | ﹤0.01% | 3981 |
|
|
2025
Q1 | $592 | Hold |
200
| – | – | ﹤0.01% | 4032 |
|
|
2024
Q4 | $610 | Hold |
200
| – | – | ﹤0.01% | 4011 |
|
|
2024
Q3 | $510 | Hold |
200
| – | – | ﹤0.01% | 3949 |
|
|
2024
Q2 | $652 | Hold |
200
| – | – | ﹤0.01% | 3842 |
|
|
2024
Q1 | $1.06K | Hold |
200
| – | – | ﹤0.01% | 3809 |
|
|
2023
Q4 | $866 | Hold |
200
| – | – | ﹤0.01% | 3813 |
|
|
2023
Q3 | $526 | Hold |
200
| – | – | ﹤0.01% | 3841 |
|
|
2023
Q2 | $706 | Hold |
200
| – | – | ﹤0.01% | 3847 |
|
|
2023
Q1 | $618 | Hold |
200
| – | – | ﹤0.01% | 3926 |
|
|
2022
Q4 | $846 | Hold |
200
| – | – | ﹤0.01% | 3944 |
|
|
2022
Q3 | $0 | Hold |
200
| – | – | ﹤0.01% | 4180 |
|
|
2022
Q2 | $1K | Hold |
200
| – | – | ﹤0.01% | 3987 |
|
|
2022
Q1 | $1K | Hold |
200
| – | – | ﹤0.01% | 3976 |
|
|
2021
Q4 | $1K | Hold |
200
| – | – | ﹤0.01% | 4011 |
|
|
2021
Q3 | $1K | Sell |
200
-310
| -61% | -$2.32K | ﹤0.01% | 3999 |
|
|
2021
Q2 | $5K | Hold |
510
| – | – | ﹤0.01% | 3619 |
|
|
2021
Q1 | $5K | Hold |
510
| – | – | ﹤0.01% | 3505 |
|
|
2020
Q4 | $5K | Hold |
510
| – | – | ﹤0.01% | 3403 |
|
|
2020
Q3 | $5K | Hold |
510
| – | – | ﹤0.01% | 3302 |
|
|
2020
Q2 | $5K | Buy |
510
+310
| +155% | +$3.21K | ﹤0.01% | 3326 |
|
|
2020
Q1 | $2K | Hold |
200
| – | – | ﹤0.01% | 3480 |
|
|
2019
Q4 | $2K | Hold |
200
| – | – | ﹤0.01% | 3493 |
|
|
2019
Q3 | $2K | Hold |
200
| – | – | ﹤0.01% | 3433 |
|
|
2019
Q2 | $3K | Hold |
200
| – | – | ﹤0.01% | 3393 |
|
|
2019
Q1 | $8K | Buy |
200
+100
| +100% | +$3.05K | ﹤0.01% | 3127 |
|
|
2018
Q4 | $2K | Hold |
100
| – | – | ﹤0.01% | 3421 |
|
|
2018
Q3 | $5K | Sell |
100
-16
| -14% | -$771 | ﹤0.01% | 3323 |
|
|
2018
Q2 | $7K | Sell |
116
-158
| -58% | -$9.16K | ﹤0.01% | 3247 |
|
|
2018
Q1 | $18K | Buy |
274
+174
| +174% | +$13K | ﹤0.01% | 2974 |
|
|
2017
Q4 | $10K | Sell |
100
-272
| -73% | -$30.4K | ﹤0.01% | 3140 |
|
|
2017
Q3 | $44K | Buy |
+372
| New | +$34.6K | ﹤0.01% | 2626 |
|
|
2017
Q1 | – | Sell |
-70
| Closed | -$2K | – | 3607 |
|
|
2016
Q4 | $2K | Buy |
+70
| New | +$3.03K | ﹤0.01% | 3391 |
|
|
2015
Q3 | – | Sell |
-57
| Closed | -$7K | – | 3653 |
|
|
2015
Q2 | $7K | Sell |
57
-425
| -88% | -$77K | ﹤0.01% | 3223 |
|
|
2015
Q1 | $113K | Sell |
482
-8
| -2% | -$1.71K | ﹤0.01% | 2090 |
|
|
2014
Q4 | $93K | Buy |
490
+119
| +32% | +$26.4K | ﹤0.01% | 2183 |
|
|
2014
Q3 | $88K | Buy |
371
+314
| +551% | +$64.5K | ﹤0.01% | 2174 |
|
|
2014
Q2 | $4K | Sell |
57
-670
| -92% | -$47.6K | ﹤0.01% | 3275 |
|
|
2014
Q1 | $76K | Buy |
727
+527
| +264% | +$61.9K | ﹤0.01% | 2277 |
|
|
2013
Q4 | $21K | Buy |
+200
| New | +$11.7K | ﹤0.01% | 2759 |
|
Other funds holding PBYI
ACA
US Bancorp's PBYI Position: Q2 2026 in Review
US Bancorp increased its Puma Biotechnology (PBYI) stake by 400% in Q2 2026, buying an estimated $5.86K and bringing the position to 1,000 shares worth $8.11K. The position accounts for ﹤0.01% of the portfolio, ranked #3518.
US Bancorp first reported a position in PBYI in Q4 2013 and has held it in 44 quarters since. The position peaked at $113K in Q1 2015. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.
- US Bancorp held 1,000 shares of Puma Biotechnology worth $8.11K as of Q2 2026.
- US Bancorp bought 800 Puma Biotechnology shares in Q2 2026, an estimated $5.86K.
- Puma Biotechnology made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3518 holding.
- US Bancorp first reported a position in Puma Biotechnology in Q4 2013 and has held it in 44 quarters since.
- US Bancorp's Puma Biotechnology position peaked at $113K in Q1 2015.
- 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.